VLA Stock Overview
A specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Valneva SE Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €3.60 |
52 Week High | €7.17 |
52 Week Low | €2.93 |
Beta | 0.97 |
11 Month Change | 9.83% |
3 Month Change | -10.27% |
1 Year Change | -42.69% |
33 Year Change | -73.39% |
5 Year Change | 16.25% |
Change since IPO | -67.17% |
Recent News & Updates
Recent updates
Valneva SE (EPA:VLA) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Aug 17Valneva SE (EPA:VLA) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 10Valneva SE's (EPA:VLA) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Apr 05Analyst Forecasts Just Became More Bearish On Valneva SE (EPA:VLA)
Mar 27Is Valneva (EPA:VLA) Weighed On By Its Debt Load?
Mar 15News Flash: Analysts Just Made A Captivating Upgrade To Their Valneva SE (EPA:VLA) Forecasts
Jan 06Valneva (EPA:VLA) Has Debt But No Earnings; Should You Worry?
Dec 13Does Valneva (EPA:VLA) Have A Healthy Balance Sheet?
Aug 10Valneva SE's (EPA:VLA) Business And Shares Still Trailing The Industry
May 12Valneva (EPA:VLA) Takes On Some Risk With Its Use Of Debt
Jan 30Is Valneva (EPA:VLA) Using Debt Sensibly?
Sep 18Shareholder Returns
VLA | FR Biotechs | FR Market | |
---|---|---|---|
7D | 8.6% | 3.4% | 3.0% |
1Y | -42.7% | -24.7% | 0.3% |
Return vs Industry: VLA underperformed the French Biotechs industry which returned -23.1% over the past year.
Return vs Market: VLA underperformed the French Market which returned 1% over the past year.
Price Volatility
VLA volatility | |
---|---|
VLA Average Weekly Movement | 8.4% |
Biotechs Industry Average Movement | 7.3% |
Market Average Movement | 4.9% |
10% most volatile stocks in FR Market | 9.8% |
10% least volatile stocks in FR Market | 2.6% |
Stable Share Price: VLA has not had significant price volatility in the past 3 months.
Volatility Over Time: VLA's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1998 | 700 | Thomas Lingelbach | valneva.com |
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus.
Valneva SE Fundamentals Summary
VLA fundamental statistics | |
---|---|
Market cap | €500.67m |
Earnings (TTM) | -€32.41m |
Revenue (TTM) | €156.47m |
3.2x
P/S Ratio-15.4x
P/E RatioIs VLA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
VLA income statement (TTM) | |
---|---|
Revenue | €156.47m |
Cost of Revenue | €156.26m |
Gross Profit | €209.00k |
Other Expenses | €32.62m |
Earnings | -€32.41m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 07, 2024
Earnings per share (EPS) | -0.23 |
Gross Margin | 0.13% |
Net Profit Margin | -20.71% |
Debt/Equity Ratio | 108.5% |
How did VLA perform over the long term?
See historical performance and comparison